Literature DB >> 7094971

Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response.

B Vandel, S Vandel, J M Jounet, G Allers, R Volmat.   

Abstract

Thirty one in-patients suffering from depression were treated orally with clomipramine (C1) at various dosage, for 28 days, after a "wash-out" period of three days. In 17 patients receiving 75 mg per day of C1, steady state plasma levels of C1 were reached at Day 14, and steady state plasma levels of its active metabolite, desmethylclomipramine (DMC1), were reached at Day 21. In contrast, in 7 other patients receiving a dosage increasing to 150 mg per day at Day 7, mean plasma levels of C1 and DMC1 continued to rise during the entire treatment period. At the steady state, a correlation was found between C1 dosage expressed as mg kg body weight and the plasma concentration of C1 and DMC1. Factors such as tobacco and alcohol consumption seem to modify the C1/DMC1 ratio. A comparison of clinical response with plasma levels of C1, DMC1 and C1 + DMC1 showed a significant negative linear correlation.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7094971     DOI: 10.1007/BF00606419

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  38 in total

1.  Plasma levels of clomipramine and its N-desmethyl metabolite following oral administration of clomipramine in man [proceedings].

Authors:  R B Jones; D K Luscombe
Journal:  Br J Pharmacol       Date:  1976-07       Impact factor: 8.739

2.  Clinical response and plasma concentration of amitriptyline and its metabolite nortriptyline.

Authors:  S Vandel; B Vandel; M Sandoz; G Allers; P Bechtel; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1978-11-27       Impact factor: 2.953

3.  Clinical responses in depressed patients in relation to plasma levels of tricyclic antidepressants and tyramine pressor response.

Authors:  L D Mulgirigama; C M Pare; P Turner; J Wadsworth; D J Witts
Journal:  Postgrad Med J       Date:  1977       Impact factor: 2.401

4.  Amitriptyline plasma concentrations and clinical response.

Authors:  S A Montgomery; R McAuley; S J Rani; D R Montgomery; R Braithwaite; S Dawling
Journal:  Br Med J       Date:  1979-06-23

5.  Influence of neuroleptics and benzodiazepines on metabolism of tricyclic antidepressants in man.

Authors:  L F Gram; K Overo; L Kirk
Journal:  Am J Psychiatry       Date:  1974-08       Impact factor: 18.112

6.  [Plasma levels of imipramine and desmethylimipramine and antidepressant effect during controlled therapy(author's transl)].

Authors:  R Oliver-Marti n; E Buschsenschultz; P Pichot; J Boissier
Journal:  Psychopharmacologia       Date:  1975

7.  Tricyclic antidepressant agents. I. Comparison of the inhibition of the uptake of 3-H-noradrenaline and 14-C-5-hydroxytryptamine in slices and crude synaptosome preparations of the midbrain-hypothalamus region of the rat brain.

Authors:  S B Ross; A L Renyi
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

8.  Benzodiazepines and tricyclic antidepressant plasma levels.

Authors:  G Silverman; R A Braithwaite
Journal:  Br Med J       Date:  1973-07-07

9.  Therapeutic implications of tricyclic antidepressant plasma levels.

Authors:  D Luchins; J Ananth
Journal:  J Nerv Ment Dis       Date:  1976-06       Impact factor: 2.254

10.  Clinical implications of imipramine plasma levels for depressive illness.

Authors:  A H Glassman; J M Perel; M Shostak; S J Kantor; J L Fleiss
Journal:  Arch Gen Psychiatry       Date:  1977-02
View more
  12 in total

1.  Tricyclic antidepressant plasma level monitoring: intraindividual variability in everyday practice.

Authors:  S Vandel; G Bertschy; S Nezeloff; B Bonin; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

2.  Fluvoxamine-tricyclic antidepressant interaction. An accidental finding.

Authors:  G Bertschy; S Vandel; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

3.  Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.

Authors:  Dorota Maciag; Kimberly L Simpson; David Coppinger; Yuefeng Lu; Yue Wang; Rick C S Lin; Ian A Paul
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

4.  Comparison of the metabolism of the three antidepressants amitriptyline, imipramine, and chlorimipramine in vitro in rat liver microsomes.

Authors:  R Krüger; G Hölzl; H J Kuss; L Schefold
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

5.  Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data.

Authors:  M Gex-Fabry; A E Balant-Gorgia; L P Balant; G Garrone
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

6.  Amitriptyline: linear or nonlinear kinetics in every day practice?

Authors:  S Vandel; G Bertschy; B Vandel; G Allers; R Volmat
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

Review 7.  Clomipramine. An overview of its pharmacological properties and a review of its therapeutic use in obsessive compulsive disorder and panic disorder.

Authors:  D McTavish; P Benfield
Journal:  Drugs       Date:  1990-01       Impact factor: 9.546

8.  Desmethylclomipramine induces the accumulation of autophagy markers by blocking autophagic flux.

Authors:  Mario Rossi; Eliana Rosa Munarriz; Stefano Bartesaghi; Marco Milanese; David Dinsdale; Maria Azucena Guerra-Martin; Edward T W Bampton; Paul Glynn; Giambattista Bonanno; Richard A Knight; Pierluigi Nicotera; Gerry Melino
Journal:  J Cell Sci       Date:  2009-08-25       Impact factor: 5.285

9.  Minor and clinically non-significant interaction between toloxatone and amitriptyline.

Authors:  S Vandel; G Bertschy; M C Perault; M Sandoz; S Bouquet; R Chakroun; S Guibert; B Vandel
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

10.  Steady-state plasma levels of clomipramine and its metabolites: impact of the sparteine/debrisoquine oxidation polymorphism. Danish University Antidepressant Group.

Authors:  K K Nielsen; K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.